Anticonvulsants in the treatment of bipolar disorder
Abstract
In the last decade, a proliferation of research has emerged concerning the use of somatic treatments with anticonvulsant properties, e.g., carbamazepine, valproate, clonazepam, oxcarbazepine, and electroconvulsive therapy (ECT), for patients with bipolar disorder. A sufficient number of controlled studies have been conducted to allow critical review of the evidence supporting the efficacy of these treatments for acute bipolar manic and depressive episodes, as well as for the prevention of subsequent episodes. Further research is needed to establish the prophylactic efficacy of anticonvulsants as maintenance therapies and, perhaps most importantly, to provide clinical and biological predictors of response.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
